The Role of Hepatitis B Core Antibody Testing in Improving Blood Safety in Resource-Limited Countries Study on Voluntary Blood Donors Fayoum, Egypt

Abdelrazik, Abeer Mohamed; Abdelaziz, Hossam M.

doi:10.4172/2155-9864.1000315

Cited by 3 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We observed 20.6% (659/3197) anti-HBc reactive donations indicating high prevalence of possible past or chronic HBV infection among Thai blood donors. Consistent with reports from other high endemic countries [12,13], 57.36% (378/659) of the anti-HBc Total reactive In summary, we have provided the first report of anti-HBc prevalence among Thai blood donors based on the donations collected from NBC and 12 RBCs. Our results demonstrate the value of anti-HBc testing for the detection of seropositive OBI cases even in a highly endemic country like Thailand.…”

Section: Discussionsupporting

confidence: 89%

Hepatitis B Core Antibody Prevalence among Voluntary Blood Donors in Thailand

Chaiwong¹,

Saekram²,

Thunnok³

et al. 2019

J Infect Dis Epidemiol

View full text Add to dashboard Cite

Introduction: Hepatitis B core (anti-HBc) antibody is an effective marker for occult Hepatitis B virus (HBV) infection and is an integral part of blood donor screening in many countries. This study was aimed to evaluate the prevalence of anti-HBc antibodies among voluntary blood donors in Thailand and its significance to reduce the risk of transfusion transmitted HBV infection. Methods: A total of 3,197 voluntary blood donor samples that were pre-screened non-reactive for HBs-Ag serology and HBV ID-NAT were tested for anti-HBc Total and IgM antibody and anti-HBs titers on ARCHITECT i6000 (Abbott Diagnostics, Illinois) between May 1, 2017 and September 31, 2017 at the National Blood Centre,

show abstract

Section: Discussionsupporting

confidence: 89%

Hepatitis B Core Antibody Prevalence among Voluntary Blood Donors in Thailand

Chaiwong¹,

Saekram²,

Thunnok³

et al. 2019

J Infect Dis Epidemiol

View full text Add to dashboard Cite

show abstract

“…Eleven anti-HBc-positive patients were anti-HBspositive. HBV-DNA was detected in seven of those 17 total anti-HBc-positive patients (7.8% of all patients) [27]. The second study included 79 poly transfused patients negative for HBsAg, HBsAb, and anti HBC Ab.…”

Section: Discussionmentioning

confidence: 99%

The role of detection of anti-HBc IgM in HBs Ag negative blood donors

Abdou

Hasssan

Gamal

et al. 2020

Journal of Recent Advances in Medicine

View full text Add to dashboard Cite

Background: Post Transfusion hepatitis B viral infection is a major problem even after adoption of mandatory screening test, HBsAg by ELISA test in blood banks. In Egypt, HBsAg is the only HBV screening test of blood donors in most bloods banks. However HBsAg negative blood donors does not rule out the risk of transmission of hepatitis B, as the donor may be in the 'window period' or has a mutant strain. During this period, detection of the antibody to the hepatitis B core antigen (anti-HBc) IgM type is a useful serological marker. Objective: this study aimed to evaluate the significance of screening anti-HBc IgM for HBsAg negative blood donors to reduce the risk of transfusion transmitted HBV infection in Egypt. Methodology: Four hundred HBsAg negative blood donors were randomly selected from Al-Zahraa University hospital blood bank, for further screening by anti-HBcIgM by ELISA test, then positive samples for anti-HBcIgM were tested for HBV DNA by PCR. Results: Nine (2.25%) out of selected 400 samples were positive for anti-HBcIgM, and 4 (1%) out of these 9 samples Conclusion: Anti HBcAg IgM screening test should be implemented as an additional screening test for blood donors in Egypt, to improve transfusion safety as it is an indicator of occult HBV during window period.

show abstract